Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2019

View Archived Issues

BLU-5937: P2X3 homotrimeric receptor antagonist with improved taste safety profile for cough

Long-term data presented from FORWARD-2 study of ALKS-5461

NRD.E1 demonstrates promising safety and efficacy in proof-of-concept study

Results from first portion of phase I study of PRN-1371 in patients with solid tumors

Location, location, location: Looking between the lines leads to neurofibromatosis insight

A novel antagonistic CD73 antibody for cancer immunotherapy presented

Fruit fly avatars identify drug sensitivity

Flu virus makes bacteria stick around

NI-956, a new prodrug inhibitor of aminopeptidase A, shows promise for hypertension treatment

Discovery of a broad-spectrum human antibody to influenza A recognizing a new site of vulnerability

FDA approves Zolgensma for spinal muscular atrophy

MIDRIXneo, a personalized vaccine as adjuvant therapy for immune checkpoint blockade

Jakafi approved by FDA for steroid-refractory acute GvHD

Aclaris Therapeutics patents JAK1 and JAK3 inhibitors

ORIC Pharmaceuticals presents CD73 inhibitors

FDA approves Piqray for HR+/HER2-, PIK3CA-mutated advanced breast cancer

Zealand Pharma describes amylin and/or calcitonin receptor agonists

Nanjing CART Medical Technologies discloses CAR T cells for hematologic cancer

Alpine Immune Sciences divulges new fusion proteins

Sensorion signs hearing loss research partnership framework agreement with Institut Pasteur

PCI Biotech begins pivotal RELEASE study of fimaChem in inoperable bile duct cancer

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

Genmab initiates phase I/IIa safety study of GEN-1046 in malignant solid tumors

OnKure begins new phase I trial of OKI-179 in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...